US securities analysts are trying to estimate the impact of the COVID-19 pandemic on the performance of medtech companies by building mathematical models that account for disruption of supply chains and the widespread deferral of elective procedures.
Following the outbreak of COVID-19 in China at the end of 2019, most medtech companies addressed the impact of COVID-19 during their most recent sales and earnings reports. Much of...